IDEEMATEC
16.3.2021 17:24:07 CET | Business Wire | Press release
Ideematec Inc. , the leading global supplier of solar tracking systems, today announced it was selected by project developer AMDA energía (AMDA) to provide customized solar tracking systems for a 100 megawatt (MW) agro photovoltaics (Agri-PV) project portfolio located in France. The innovative systems will deliver synergistic solutions for the production of organic food crops and clean electricity generation all while providing soil protection and water savings, helping farmers to move towards a low-emissions smart farming labelling.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210316005876/en/
The 100 MW portfolio will be composed of multiple 5 MW projects and will meet specific requirements for proper construction on agricultural land in accordance with local regulations.
Ideematec’s engineering team has modified and optimized the Horizon L:TEC tracker model by adjusting the axis heights of the tracker and maximizing the rotation angle for the module to +/- 70 degrees, allowing the trackers to operate synergistically with agricultural equipment. Ideematec also designed an Agri-PV-specific control and agronomic-orientated monitoring system to improve crop production, land quality and address specific needs of each Agri-PV project site.
“Agri-PV projects require flexibility in both the hardware and installation to protect the integrity of the land and ensure that agricultural practices can operate effectively, while harnessing the benefits of clean energy,” said Jorge Gutiérrez Serra, President for AMDA. “We are confident that Ideematec’s durable and customizable solar trackers will fit the needs of an innovative energy system optimized for highly profitable agricultural production for years to come.”
“Our two-in-portrait (2P) module wings, equipped with bifacial modules, allow us to space module rows to support efficient agricultural operations, such as moving large vehicles between module rows, or monitoring sites for agricultural variables to increase generation efficiency,” says Mario Eckl, Co Founder & CEO Ideematec. “These innovations allow our trackers to provide reliable clean energy to projects at scale, without disturbing the local environment or quality of land. The Agri-PV sector is poised for tremendous growth and we are eager to support agricultural-friendly solutions.”
Agricultural-friendly utility-scale solar solutions are growing in popularity in Europe, and Ideematec expects that trend to erupt in both the North American and APAC markets in the coming years, as rural communities find ways to support scaled renewable energy deployment and generate multiple sources of revenue with agricultural lands.
About Ideematec, Inc.
Ideematec, Inc. is a trusted global supplier of solar tracking systems, headquartered in Germany. Established in 2003, the company serves as a pure play tracker provider for the utility-scale sector. Ideematec pioneered the 2P high-span safeTrack Horizon™ tracker, powered by a patented dual drive technology. Since 2017, the company has successfully delivered some of the biggest solar facilities on three continents, including Jordan (250 MW), Australia (350 MW) and Spain (200 MW). For more information please visit: http://www.ideematec.com/
About AMDA energía
AMDA energía is an international global developer focused on the promotion, development and funding of renewable energy generation projects around the world with proven track record in both photovoltaic and wind sectors having developed more than 30 projects in on 3 different continents since it was created in 2008 (Spain, Portugal, France, South Africa, Mozambique, Tunisia, Colombia, Mexico). Thanks to its experienced staff, the core activities cover the complete process of development of a large-scale renewable energy project.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005876/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom